Clinuvel Pharmaceuticals (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.
Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.
Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.
The company's shares slipped 2% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。